Heron Therapeutics, Inc.
NASDAQ•HRTX
CEO: Mr. Craig Alexander Collard
Sector: Healthcare
Industry: Biotechnology
Listing Date: 1987-08-26
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
Contact Information
Market Cap
$235.33M
P/E (TTM)
-18.7
38.2
Dividend Yield
--
52W High
$2.68
52W Low
$1.00
52W Range
Rank68Top 98.2%
1.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$38.21M+16.47%
4-Quarter Trend
EPS
-$0.10+215.46%
4-Quarter Trend
FCF
$1.33M-54.73%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Total Sales Increased 10.4% Nine months net product sales reached $114.3M USD, up 10.4% versus prior year, driven by strong acute care performance.
Acute Care Sales Surge Acute care net sales grew 69.2% to $33.3M USD for nine months, fueled by ZYNRELEF and APONVIE unit volume increases.
Operating Loss Significantly Reduced Loss from operations narrowed to $2.6M USD for nine months, a substantial improvement from $15.7M loss reported previously.
Gross Margin Improved Nine months gross profit margin increased to 73.6% compared to 72.5% last year, despite higher cost of product sales percentage.
Risk Factors
Oncology Sales Face Competition Oncology net product sales decreased 3.4% for nine months due to market competition from branded products and generics.
Inventory Write-Offs Impact Costs Cost of product sales included $2.7M USD in inventory reserves and write-offs for the nine months ended September 30, 2025.
Ongoing Patent Litigation Exposure Vigorous enforcement of CINVANTI and APONVIE intellectual property rights continues against multiple generic challengers currently.
Cash Burn Increased Net cash used in operating activities rose to $18.4M USD for nine months, reflecting increased inventory and liability payments.
Outlook
Winding Down SUSTOL Commercialization Intends to wind down SUSTOL commercialization over next 12 months while evaluating potential product updates and reintroduction timing.
Liquidity Sufficient One Year Cash, cash equivalents, and short-term investments of $55.5M USD are projected to meet anticipated cash requirements for at least one year.
Debt Refinancing Completed Executed significant debt refinancing, including 2031 Notes issuance and 2026 Notes exchange, resulting in $11.3M loss on extinguishment.
Advance Product Candidates Focus remains on developing, acquiring, and advancing product candidates through clinical trials and securing necessary regulatory approvals.
Peer Comparison
Revenue (TTM)
$155.10M
CHRS$83.57M
$52.93M
Gross Margin (Latest Quarter)
SGMO100.0%
71.3%
CHRS67.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| HRTX | $235.33M | -18.7 | 72.9% | 56.4% |
| CGEN | $220.74M | -8.0 | -53.6% | 3.0% |
| OABI | $204.48M | -3.4 | -23.1% | 6.8% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.1%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention
Research & Insights
Next earnings:Feb 26, 2026
EPS:-$0.03
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 4, 2025|Revenue: $38.21M+16.5%|EPS: $-0.10+215.5%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 8, 2025|Revenue: $37.20M+3.3%|EPS: $-0.02-67.0%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 6, 2025|Revenue: $38.90M+12.2%|EPS: $0.02-182.3%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 27, 2025|Revenue: $144.29M+13.6%|EPS: $-0.09+88.9%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 12, 2024|Revenue: $32.81M+4.4%|EPS: $-0.03-81.4%MeetForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 6, 2024|Revenue: $36.02M+13.4%|EPS: $-0.06-82.7%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 7, 2024|Revenue: $34.67M+17.1%|EPS: $-0.02-92.3%BeatForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Mar 12, 2024|Revenue: $127.04M+18.0%|EPS: $-0.80+52.1%Miss